FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL

OMB Number: Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* HOWELL LLOYD JR						IN	2. Issuer Name and Ticker or Trading Symbol INTEGRA LIFESCIENCES HOLDINGS CORP [IART]									Check all	applicable) irector	oplicable) ector		Person(s) to Issuer 10% Owner	
(Last) (First) (Middle) 311 ENTERPRISE DRIVE							3. Date of Earliest Transaction (Month/Day/Year) 11/30/2016										Officer (give title below)		Other below)	(specify	
(Street) PLAINSBORO NJ 08536 (City) (State) (Zip)					4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)									S. Individual or Joint/Group Filing (Check Applicable ine) X Form filed by One Reporting Person Form filed by More than One Reporting Person						
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																					
1. Title of Security (Instr. 3) 2. Transa Date (Month/D						2A. Deemed Execution Date if any (Month/Day/Ye			on Date,	Code	ities Acquired (A) d Of (D) (Instr. 3, 4			nd Se Be Ow	Amount of curities neficially ned Following	For (D)	Ownership rm: Direct or Indirect (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
											v	Amount		A) or D)	Price	Tra	nsaction(s) tr. 3 and 4)			(msu. 4)	
Common Stock 11/30/						0/2016	/2016			G	V	1,884	1	D	\$ <mark>0</mark> .	00	16,048		D		
			Та	ble II - D								sed of, onvertib				y Own	ed				
1. Title of Derivative Security (Instr. 3)	2. Conversio or Exercis Price of Derivative Security	se (Month/Day/Yea		3A. Deems Execution if any (Month/Da	Date,		Transaction Code (Instr.		of Derivative (Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		5. Date Exercisable and Expiration Date Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. : and 4)		8. Price Derivati Security (Instr. 5)	derivative Securities	у	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
						Code	Code V		(D)	Date Exercisa		Expiration Date	Title	of Sha	res						

Explanation of Responses:

Remarks:

/s/ Richard D. Gorelick; 12/05/2016 Attorney-in-Fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Know all by these presents, that the undersigned hereby authorizes Amritpal Deol, Lisa Evoli, Richard D. Gorelick, Mythili Seshan, David Sirolly and Barbara Vietor to execute for and on behalf of the undersigned Forms 3, 4 and 5, and any amendments thereto, and cause such form(s) to be filed with the United States Securities and Exchange Commission pursuant to Section 16(a) of the Securities Act of 1934, relating to the undersigned's beneficial ownership of securities in Integra LifeSciences Holdings Corporation (the "Company"). The undersigned also authorizes the above persons to execute for and on behalf of the undersigned any Form ID or similar document required to obtain or renew Securities and Exchange Commission electronic filings codes and passwords and cause such form(s) to be submitted to and/or filed with the Securities and Exchange Commission. The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned's holdings of, and transactions in, securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 5th day of December, 2016.

/s/ Lloyd Howell, Jr. Lloyd Howell, Jr.